Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human Use

Molecular Imaging and Biology

Volumn 19, Issue 4, 2017, Pages 512-521

  Samkoe, Kimberley S ^a,b   Gunn, Jason R ^b   Marra, Kayla ^b   Hull, Sally M ^b   Moodie, Karen L ^c   Feldwisch, Joachim ^d   Strong, Theresa V ^e   Draney, Daniel R ^f   Hoopes, P Jack ^a,b,c   Roberts, David W ^a,b   Paulsen, Keith ^a,b   Pogue, Brian W ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH COLLEGE   (United States)

^c DARTMOUTH COLLEGE   (United States)

^d Affibody AB   (Sweden)

^e UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^f LI COR BIOSCIENCES   (United States)

Author keywords

ABY 029; Affibody; EGFR; Epidermal growth factor receptor; Fluorescence guided surgery; Glioma; IRDye 800CW

Indexed keywords

ABY 029; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOTOSENSITIZING AGENT; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; HYBRID PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CLEARANCE; CLINICAL CHEMISTRY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SAFETY; FEMALE; FLUORESCENCE IMAGING; HISTOPATHOLOGY; MALE; NONHUMAN; PHOTOTOXICITY; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; DRUG EFFECTS; FLUORESCENCE; HUMAN; INJECTION; LIGHT; METABOLISM; ORGAN SIZE; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALS; BODY WEIGHT; FEMALE; FLUORESCENCE; HUMANS; INJECTIONS; LIGHT; MALE; ORGAN SIZE; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION;

EID: 85000956557     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-016-1033-y     Document Type: Article

References (44)

1. DSouza AV, Lin H, Elliott JT et al (2016) Review of fluorescence guidance systems: identification of key performance capabilities beyond indocyanine green imaging. JBO 21:080901
2. Vahrmeijer AL, Frangioni JV (2011) Seeing the invisible during surgery. Br J Surg 98:749
3. Stummer W, Stepp H, Möller G et al (1998) Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resection of malignant glioma tissue. Acta Neurochir 140:995–1000
4. Stummer W, Tonn J-C, Goetz C et al (2014) 5-Aminolevulinic acid-derived tumor fluorescence: the diagnostic accuracy of visible fluorescence qualities as corroborated by spectrometry and histology and postoperative imaging. Neurosurgery 74:310–320
5. Roberts DW, Valdés PA, Harris BT et al (2011) Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between δ-aminolevulinic acid–induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. J Neurosurg 114:595
6. Roberts DW, Valdés PA, Harris BT et al (2012) Glioblastoma multiforme treatment with clinical trials for surgical resection (aminolevulinic acid). Neurosurg Clin N Am 23:371–377
7. Valdés PA, Kim A, Brantsch M et al (2011) δ-Aminolevulinic acid–induced protoporphyrin IX concentration correlates with histopathologic markers of malignancy in human gliomas: the need for quantitative fluorescence-guided resection to identify regions of increasing malignancy. Neuro-Oncology 13:846–856
8. Stummer W, Pichlmeier U, Meinel T et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401
9. Stummer W, Reulen H-J, Meinel T et al (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:564–576
10. Ekstrand AJ, James CD, Cavenee WK et al (1991) Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51:2164–2172
11. Zimmermann M, Zouhair A, Azria D, Ozsahin M (2006) The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol J 1:11
12. Barrett T, Koyama Y, Hama Y et al (2007) In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res 13:6639–6648
13. Gleysteen JP, Newman JR, Chhieng D, Frost A, Zinn KR, Rosenthal EL (2008) Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model. Head Neck 30:782–789
14. Helman EE, Newman JR, Dean NR et al (2010) Optical imaging predicts tumor response to anti-EGFR therapy. Cancer Biol Ther 10:166–171
15. Koyama Y, Barrett T, Hama Y et al (2007) In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia 9:1021–1029
16. Kulbersh BD, Duncan RD, Magnuson JS et al (2007) Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts. Arch Otolaryngol Head Neck Surg 133:511–515
17. Rosenthal EL, Warram JM, de Boer E et al (2015) Safety and tumor-specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer. Clin Cancer Res 21:3658–3666
18. Verbeek FP, van der Vorst JR, Tummers QR et al (2014) Near-infrared fluorescence imaging of both colorectal cancer and ureters using a low-dose integrin targeted probe. Ann Surg Oncol 21:528–537
19. Wang K, Wang K, Li W et al (2009) Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging. Acta Radiol 50:1095–1103
20. Day K, Sweeny L, Kulbersh B et al (2013) Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Mol Imaging Biol 15:722–729
21. Heath CH, Deep N, Sweeny L et al (2012) Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model. Ann Surg Oncol 19:3879–3887
22. Rosenthal EL, Kulbersh BD, Duncan RD et al (2006) In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence. Laryngoscope 116:1636–1641
23. Rosenthal EL, Kulbersh BD, King T et al (2007) Use of fluorescent labeled anti–epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts. Mol Cancer Res 6:1230–1238
24. Löfblom J, Feldwisch J, Tolmachev V et al (2010) Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 584:2670–2680
25. Feldwisch J, Tolmachev V (2012) Engineering of Affibody molecules for therapy and diagnostics. Therapeutic Proteins: Methods and Protocols:103–126
26. Tolmachev V, Orlova A, Nilsson FY et al (2007) Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther 7:555–568
27. Sandström M, Lindskog K, Velikyan I et al (2016) Biodistribution and radiation dosimetry of the anti-HER2 Affibody molecule 68Ga-ABY-025 in breast cancer patients. J Nucl Med 57:867–871
28. Sörensen J, Sandberg D, Sandström M et al (2014) First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J Nucl Med 55:730–735
29. Sörensen J, Velikyan I, Sandberg D et al (2015) Measuring HER2-receptor expression in metastatic breast cancer using [68 Ga] ABY-025 Affibody PET/CT. Theranostics 6:262–271
30. Baum RP, Prasad V, Müller D et al (2010) Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled Affibody molecules. J Nucl Med 51:892–897
31. Marshall MV, Draney D, Sevick-Muraca E, Olive DM (2010) Single-dose intravenous toxicity study of IRDye 800CW in Sprague-Dawley rats. Mol Imaging Biol 12:583–594
32. van Scheltinga AGT, van Dam GM, Nagengast WB et al (2011) Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med 52:1778–1785
33. Hekman M, Mulders P, de Weijert M et al (2015) Ex vivo perfusion of tumorous kidneys with a dual-modality imaging probe. J Nucl Med 56:1209
34. Ribeiro de Souza, AL, Marra K, Gunn J, et al. (2016) Fluorescent Affibody molecule administered in vivo at a microdose level labels EGFR expressing glioma tumor regions. Mol Imaging Biol First Online 05 July 2016:1–8
35. Sexton K, Tichauer K, Samkoe KS et al (2013) Fluorescent Affibody peptide penetration in glioma margin is superior to full antibody. PLoS One 8:e60390
36. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659–661
37. Giknis M, Clifford C (2006) Clinical laboratory parametes for Crl:CD (SD) rats. Charles River Laboratories:1–14
38. Lillie LE, Temple NJ, Florence LZ (1996) Reference values for young normal Sprague-Dawley rats: weight gain, hematology and clinical chemistry. Hum Exp Toxicol 15:612–616
39. Friedman M, Orlova A, Johansson E et al (2008) Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol 376:1388–1402
40. Mitsunaga M, Ogawa M, Kosaka N et al (2011) Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med 17:1685–1691
41. Group ToA-rMDWPTS (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report 1. Arch Ophthalmol 117:1329
42. Miller JW, Schmidt-Erfurth U, Sickenberg M et al (1999) Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 117:1161–1173
43. Schmidt-Erfurth U, Miller JW, Sickenberg M et al (1999) Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 117:1177–1187
44. Chung H, Dai T, Sharma SK et al (2012) The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng 40:516–533